SG11201507181YA - Method for the treatment of fatty liver disease - Google Patents
Method for the treatment of fatty liver diseaseInfo
- Publication number
- SG11201507181YA SG11201507181YA SG11201507181YA SG11201507181YA SG11201507181YA SG 11201507181Y A SG11201507181Y A SG 11201507181YA SG 11201507181Y A SG11201507181Y A SG 11201507181YA SG 11201507181Y A SG11201507181Y A SG 11201507181YA SG 11201507181Y A SG11201507181Y A SG 11201507181YA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- liver disease
- fatty liver
- fatty
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/801,697 US20140274979A1 (en) | 2013-03-13 | 2013-03-13 | Method for the treatment of fatty liver disease |
| PCT/US2013/072092 WO2014158242A1 (en) | 2013-03-13 | 2013-11-26 | Method for the treatment of fatty liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507181YA true SG11201507181YA (en) | 2015-10-29 |
Family
ID=51529924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507181YA SG11201507181YA (en) | 2013-03-13 | 2013-11-26 | Method for the treatment of fatty liver disease |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20140274979A1 (en) |
| EP (1) | EP2968217B1 (en) |
| JP (1) | JP6377713B2 (en) |
| KR (1) | KR20150130352A (en) |
| CN (1) | CN105209028B (en) |
| BR (1) | BR112015022571A2 (en) |
| ES (1) | ES2730739T3 (en) |
| HK (1) | HK1216614A1 (en) |
| MX (1) | MX2015012455A (en) |
| SG (1) | SG11201507181YA (en) |
| TW (1) | TWI631943B (en) |
| WO (1) | WO2014158242A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10925854B2 (en) * | 2015-11-19 | 2021-02-23 | Sinew Pharma Inc. | Methods and compositions for preventing or treating fatty liver, protecting liver function or ameliorating liver diseases caused by fatty liver or other associated disorders |
| CN107343890A (en) * | 2016-05-06 | 2017-11-14 | 北京大学 | The application of Antrodia camphorata and monomer lanostane 32 in NASH is prevented and treated |
| JP2019514986A (en) * | 2016-05-13 | 2019-06-06 | ゴールデン バイオテクノロジー コーポレーション | Methods and compositions for treating advanced non-small cell lung cancer |
| AU2017331260A1 (en) | 2016-09-23 | 2019-05-16 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
| CN113795258B (en) * | 2019-02-25 | 2024-04-16 | 吉亚生技控股股份有限公司 | Methods and compositions for inhibiting viral infection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101516835A (en) * | 2006-07-19 | 2009-08-26 | 俄亥俄州立大学研究基金会 | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
| CA2658096A1 (en) * | 2006-07-19 | 2008-01-24 | Osurf (Ohio State University Research Foundation) | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
| JP2008260695A (en) * | 2007-04-10 | 2008-10-30 | Nissei Bio Kk | Hepatopathy inhibitor |
| TWI394573B (en) * | 2007-06-14 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection |
| CN101785793A (en) * | 2009-01-23 | 2010-07-28 | 伟诚生物科技有限公司 | Application of antradiacomphora extract capsule for protecting liver and promoting body immune regulation function |
| JP5800368B2 (en) * | 2010-05-19 | 2015-10-28 | 興和株式会社 | Preventive and / or therapeutic agent for nonalcoholic steatohepatitis |
| US8309611B2 (en) * | 2010-09-20 | 2012-11-13 | Golden Biotechnology Corporation | Methods and compositions for treating lung cancer |
-
2013
- 2013-03-13 US US13/801,697 patent/US20140274979A1/en not_active Abandoned
- 2013-11-26 KR KR1020157027353A patent/KR20150130352A/en not_active Application Discontinuation
- 2013-11-26 ES ES13880440T patent/ES2730739T3/en active Active
- 2013-11-26 CN CN201380074591.0A patent/CN105209028B/en active Active
- 2013-11-26 EP EP13880440.6A patent/EP2968217B1/en active Active
- 2013-11-26 SG SG11201507181YA patent/SG11201507181YA/en unknown
- 2013-11-26 WO PCT/US2013/072092 patent/WO2014158242A1/en active Application Filing
- 2013-11-26 BR BR112015022571A patent/BR112015022571A2/en not_active IP Right Cessation
- 2013-11-26 MX MX2015012455A patent/MX2015012455A/en unknown
- 2013-11-26 JP JP2016500112A patent/JP6377713B2/en active Active
-
2014
- 2014-01-09 TW TW103100845A patent/TWI631943B/en active
-
2016
- 2016-04-22 HK HK16104631.9A patent/HK1216614A1/en unknown
-
2017
- 2017-06-26 US US15/633,719 patent/US20170304224A1/en not_active Abandoned
-
2019
- 2019-11-29 US US16/699,405 patent/US10959963B2/en active Active
-
2021
- 2021-02-20 US US17/180,781 patent/US20210177775A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2968217B1 (en) | 2019-03-13 |
| JP6377713B2 (en) | 2018-08-22 |
| MX2015012455A (en) | 2016-04-07 |
| BR112015022571A2 (en) | 2017-07-18 |
| HK1216614A1 (en) | 2016-11-25 |
| WO2014158242A1 (en) | 2014-10-02 |
| CN105209028A (en) | 2015-12-30 |
| CN105209028B (en) | 2019-06-14 |
| EP2968217A1 (en) | 2016-01-20 |
| TWI631943B (en) | 2018-08-11 |
| KR20150130352A (en) | 2015-11-23 |
| US20140274979A1 (en) | 2014-09-18 |
| EP2968217A4 (en) | 2016-11-02 |
| ES2730739T3 (en) | 2019-11-12 |
| US10959963B2 (en) | 2021-03-30 |
| US20170304224A1 (en) | 2017-10-26 |
| TW201440759A (en) | 2014-11-01 |
| JP2016512238A (en) | 2016-04-25 |
| US20200093757A1 (en) | 2020-03-26 |
| US20210177775A1 (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1218078A1 (en) | Drug for treatment of nonalcoholic fatty liver disease | |
| IL243976A0 (en) | Kdm1a inhibitors for the treatment of disease | |
| HK1225305A1 (en) | Methods and compositions for treating brain diseases | |
| SG11201701723XA (en) | Methods of treating liver disease | |
| EP2958936A4 (en) | Methods and compositions for treatment of forbes-cori disease | |
| IL244042A0 (en) | Method for the treatment of fibrotic disease | |
| HK1219653A1 (en) | Methods for the treatment of mitochondrial disease | |
| IL245474B (en) | Process for the preparation of 5-fluoro-1h-pyrazoles | |
| HK1216614A1 (en) | Method for the treatment of fatty liver disease | |
| IL245476A0 (en) | Process for the preparation of 5-fluoro-1h-pyrazoles | |
| HK1223547A1 (en) | Methods for the treatment of cancer | |
| IL243637A0 (en) | Ppar-sparing compounds for the treatment of metabolic diseases | |
| IL241096B (en) | Method of treatment | |
| PT3038596T (en) | Compositions and methods for the removal of tattoos | |
| EP3021873A4 (en) | Methods for the treatment of inflammatory joint disease | |
| IL229326A (en) | Process for the preparation of n-iodoamides | |
| HK1221681A1 (en) | Methods for the treatment of neurodegeneration | |
| PL3233074T3 (en) | Treatment for non-alcoholic fatty liver diseases | |
| GB201301975D0 (en) | New method for the purpose of safening | |
| IL246188B (en) | Process for the preparation of tiacumicin | |
| GB201321628D0 (en) | Treatment of disease | |
| GB201322778D0 (en) | Method of treatment | |
| GB201314882D0 (en) | Method of treatment |